Tyenne (tocilizumab-aazg) injection recalled for glass particles
Fresenius Kabi USA discovered that Tyenne (tocilizumab-aazg) Injection vials may contain glass particles. The contamination was found during an internal investigation. The affected lot is 16UI07, which expires August 31, 2028.
From the FDA notice · Read the official notice ↗ · All Fresenius Kabi recalls
What to do
- If you have received this medication, do not use it.
- Contact your healthcare provider or pharmacist immediately for a replacement.
- Check your vials for any visible particles before use.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Units affected
- 4,643 20mL-vials
- Illnesses reported
- None reported
- Manufactured in
- 3 Corporate Dr, N/A, Lake Zurich, IL, United States
- Classification
- Class I
- Recall number
- D-0827-2026
In the FDA's words
- Description
- Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20. Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles. Lot: 16UI07, Exp 08/31/2028 Distribution: Nationwide in the USA Affected quantity: 4,643 20mL-vials
- Hazard
- Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
More from Fresenius Kabi
See all- Fresenius Kabi morphine syringes recalled for Dilaudid label mixup
SeriousFDAAug 26, 2026